Table 3.

Sustained Virologic Response Rates in Genotype 1–Infected Patients by Duration of Treatment, Cirrhosis, and Prior Treatment

	LDV/SOF		LDV/SOF+RIBA		PrOD		PrOD+RIBA
	n	SVR, % (95% CI)	n	SVR, % (95% CI)	n	SVR, % (95% CI)	n	SVR, % (95% CI)
Treatment-naïve
No cirrhosis
All durations	4485	93.4 (92.6–94.0)	522	96.7 (94.8–98.0)	519	95.8 (93.6–97.2)	1135	91.6 (89.9–93.1)
12 wk	2101	95.6 (94.7–96.4)	404	98.5 (96.7–99.3)	448	97.8 (95.9–98.8)	930	95.8 (94.3–96.9)
24 wk	NR	NR	NR	NR	NR	NR	NR	NR
Cirrhosis
All durations	1131	90.1 (88.2–91.7)	579	89.5 (86.7–91.7)	34	97.1 (80.2–99.6)	445	93.0 (90.3–95.1)
12 wk	798	92.0 (89.9–93.7)	468	91.2 (88.3–93.5)	23	100	350	97.4 (95.1–98.7)
24 wk	141	92.2 (86.4–95.7)	22	95.5 (70.4–99.5)	NR	NR	NAa	NAa
Treatment-experienced
No cirrhosis
All durations	1237	94.1 (92.6–95.3)	538	94.4 (92.1–96.1)	138	91.3 (85.2–95.0)	373	93.6 (90.6–95.7)
12 wk	806	96.7 (95.2–97.7)	424	95.0 (92.5–96.8)	114	99.1 (93.9–99.9)	298	95.6 (92.6–97.5)
24 wk	147	96.6 (92.0–98.6)	NR	NR	NR	NR	NR	NR
Cirrhosis
All durations	559	91.2 (88.6–93.3)	861	89.4 (87.2–91.3)	13	92.3 (53.1–99.2)	175	94.3 (89.6–96.9)
12 wk	127	94.5 (88.8–97.4)	668	89.4 (86.8–91.5)	NA	NAa	132	98.5 (94.0–99.6)
24 wk	332	93.7 (90.5–95.8)	85	94.1 (86.4–97.6)	NR	NR	NA	NAa

NA, not available; NR, not recommended for the specific subpopulation.

^aRegimens with <20 patients.